title: Sorafenib - a small molecule with big promise?
authors.affiliation: Hematology-Oncology Unit, Bnai-Zion Medical Center, Haifa, Israel. tamar.tadmor@b-zion.org.il
authors.forename: Tamar
authors.initials: T
authors.lastname: Tadmor
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
authors.forename: Aaron
authors.initials: A
authors.lastname: Polliack
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced; D000208:Acute Disease; D019540:Area Under Curve; D001557:Benzenesulfonates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008657:Metabolic Clearance Rate; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009325:Nausea / Q000139:chemically induced; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D048049:Extracellular Signal-Regulated MAP Kinases